T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| 1 |
Schlumberger
SLB
|
$2.5B |
| 2 |
Kenvue
KVUE
|
$1.3B |
| 3 |
Halliburton
HAL
|
$1.16B |
| 4 |
Charles Schwab
SCHW
|
$836M |
| 5 |
Boeing
BA
|
$832M |
Top Sells
| 1 |
Microsoft
MSFT
|
$2.52B |
| 2 |
Apple
AAPL
|
$1.77B |
| 3 |
Advanced Micro Devices
AMD
|
$1.57B |
| 4 |
Johnson & Johnson
JNJ
|
$1.47B |
| 5 |
Intuit
INTU
|
$1.14B |
Sector Composition
| 1 | Technology | 29.85% |
| 2 | Healthcare | 16.84% |
| 3 | Financials | 10.89% |
| 4 | Consumer Discretionary | 10.77% |
| 5 | Communication Services | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AIV
476
Aimco
AIV
$1.11B
| $121M | 0.02% |
17,759,083
-187,733
| -1% | -$1.28M |
|
477
MoonLake Immunotherapeutics
MLTX
$3.77B
| $121M | 0.02% |
2,117,868
+174,812
| +9% | +$9.96M |
|
478
East-West Bancorp
EWBC
$14.8B
| $121M | 0.02% |
2,288,705
-27,020
| -1% | -$1.42M |
|
|
CERE
479
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $120M | 0.02% |
5,503,498
+278,698
| +5% | +$6.08M |
|
480
Acadia Realty Trust
AKR
$2.63B
| $118M | 0.02% |
8,236,964
+1,113,166
| +16% | +$16M |
|
481
HDFC Bank
HDB
$361B
| $118M | 0.02% |
2,002,271
-32,869
| -2% | -$1.94M |
|
482
KT
KT
$9.78B
| $118M | 0.02% |
9,207,907
+1,395,897
| +18% | +$17.9M |
|
483
Apple Hospitality REIT
APLE
$3.09B
| $117M | 0.02% |
7,621,524
+1,828,643
| +32% | +$28.1M |
|
484
Snap
SNAP
$12.4B
| $115M | 0.02% |
12,959,020
+11,454,136
| +761% | +$102M |
|
|
CHX
485
DELISTED
ChampionX
CHX
| $115M | 0.02% |
3,241,209
+67,727
| +2% | +$2.41M |
|
486
Exact Sciences
EXAS
$10.2B
| $115M | 0.02% |
1,683,334
-498,552
| -23% | -$34M |
|
487
Ares Management
ARES
$38.9B
| $115M | 0.02% |
1,114,998
-64,761
| -5% | -$6.66M |
|
488
Idexx Laboratories
IDXX
$51.4B
| $114M | 0.02% |
260,923
+52,903
| +25% | +$23.1M |
|
489
Roblox
RBLX
$88.5B
| $113M | 0.02% |
3,908,050
-3,493,274
| -47% | -$101M |
|
490
Ultragenyx Pharmaceutical
RARE
$3.07B
| $113M | 0.02% |
3,160,160
-454,832
| -13% | -$16.2M |
|
491
Camden Property Trust
CPT
$11.9B
| $112M | 0.02% |
1,187,525
+45,225
| +4% | +$4.28M |
|
492
ScottsMiracle-Gro
SMG
$3.64B
| $112M | 0.02% |
2,158,069
-96,683
| -4% | -$5M |
|
493
10x Genomics
TXG
$1.74B
| $111M | 0.02% |
2,687,451
+30,127
| +1% | +$1.24M |
|
494
News Corp Class B
NWS
$18.8B
| $111M | 0.02% |
5,310,922
+125,225
| +2% | +$2.61M |
|
495
Alexandria Real Estate Equities
ARE
$14.5B
| $110M | 0.02% |
1,103,473
-119,925
| -10% | -$12M |
|
496
Acadia Pharmaceuticals
ACAD
$4.26B
| $109M | 0.02% |
5,230,161
-783,753
| -13% | -$16.3M |
|
497
Paychex
PAYX
$48.7B
| $109M | 0.02% |
941,825
+5,527
| +0.6% | +$637K |
|
498
Grupo Aeroportuario del Pacifico
PAC
$12.6B
| $108M | 0.02% |
659,005
-13,787
| -2% | -$2.27M |
|
499
Bruker
BRKR
$4.68B
| $108M | 0.02% |
1,729,392
-316,923
| -15% | -$19.7M |
|
500
Johnson Controls International
JCI
$69.5B
| $107M | 0.02% |
2,013,861
+323,244
| +19% | +$17.2M |
|